francis h burr proton therapy center NUMBER mev cyclotron proton beams directed isocentric gantries stereotactic intracranial beam line eye line improved physical dose distribution proton radiotherapy allows dose escalation improve local tumor control anatomic sites histologies local control suboptimal photons improved dose localization reduces doses anticipated reduction acute late toxicity clinical treatment protocols developed exploit dosimetric advantages protons photons grouped broad categories dose escalated anatomic sites local control conventional radiation doses suboptimal second sparing protons designed minimize acute late toxicity treatment patients clinical research protocols encouraged patient treatments began gantry november NUMBER eye line april NUMBER second gantry NUMBER stereotactic intracranial line august NUMBER facility currently treats NUMBER patients day including children daily anesthesia studies completed early stage prostate cancer conjunction loma linda university sarcomas cervical skull thoracolumbosacral spine protocols progress development carcinoma nasopharynx paranasal sinus carcinoma lung carcinoma locally advanced carcinoma prostate hepatocellular carcinoma pancreatic cancer studies evaluating use protons morbidity reduction include protocols craniospinal irradiation conjunction systemic chemotherapy medulloblastoma retinoblastoma pediatric rhabdomyosarcoma pediatric sarcomas accelerated hypofractionated partial breast irradiation t1n0 breast carcinomas pediatric patients protons accepted alternative photons children enrolled childrens oncology group cog protocols treatment patients studies required development new treatment techniques matching abutting fields craniospinal irradiation respiratory gating development appropriate clinical infrastructure support increase availability pediatric anesthesia allow appropriate treatment addition clinical research infrastructure protocol development data management required results date indicate proton radiation therapy offers potential treatment advantages patients studied setting clinical trials patients willingness enter clinical trials quite high accrual selected studies favorable normal tissue normal tissue dose escalation non small cell spine base